SCHEMBL17830722

SCHEMBL17830722

Cc1ccc(COC(=O)Cn2c(=O)oc3cc(Cl)ccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.55
ALDH1A1 P00352 4/20 0.52
USP2 O75604 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.49
TP53 P04637 4/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 2/20 0.48
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MIF P14174 2/20 0.46
PKM P14618 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830724 0.93 IDO1 (0.51) RECQLALDH1A1USP2POLBTP53
SCHEMBL17830721 0.89 TP53 (0.59) RECQLALDH1A1USP2POLBTP53
SCHEMBL17830726 0.89 IDO1 (0.55) RECQLALDH1A1USP2POLBTP53
SCHEMBL17830715 0.89 PIK3CB (0.54) ALDH1A1USP2POLBTP53MAPT
SCHEMBL17830723 0.88 PKM (0.53) RECQLALDH1A1USP2L3MBTL1POLB
SCHEMBL17830732 0.87 USP2 (0.47) ALDH1A1USP2POLBTP53MAPT
SCHEMBL17830728 0.86 ALDH1A1 (0.45) RECQLALDH1A1USP2POLBTP53
SCHEMBL17830725 0.85 POLB (0.52) ALDH1A1USP2POLBTP53MAPT
SCHEMBL17830734 0.85 IDO1 (0.52) RECQLALDH1A1USP2POLBTP53
SCHEMBL5298443 0.84 MIF (0.64) RECQLALDH1A1L3MBTL1POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A RECQL 4595/4885ALDH1A1 4832/4885USP2 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.